still no updates as per their last release "Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program."
the criminals known as RVX mgmt have been LYING to us for YEARS.... now we're shutting P2 down "early", notifying us how exactly? with a line buried in a related news release? if ti's stopped, give us the full picture. dont just insert a random statement like that buried in a NR.
where's the formal announcement? are they still tabulating the failed results? how on earth they can get away w/ "notifying" the rest of us about the conclusion of P2 like that? last to know. mr market seems to have known this allllllll along, fast approaching 30c OR LESS.
i suppose it's PAR FOR THE COURSE with their terribly poor written communications. when did i miss the big expanded role that is promised to eversana? Now we owe them 8.1M? FOR WHAT? WHUT The FKCU have they done for us exactly?
and now we've GIVEN AWAY Cario and PAH to eversana?
the lights are off at the company, broke, pi$$ poor management making mateiral decisions but not updating us... this weak management has to stop!!!!!
As at March 31, 2022, Trade and other payables included $8.1 million owing to Eversana. A discount of $0.2 million on the pre-commercialization fees incurred in the three months ended March 31, 2022 has been recognized as an offset to the long-term deferred fees liability and to precommercialization expenses to reflect the financing component of the deferred fees; the discount will be accreted over the term that is projected until settlement. $0.6 million of deferred fees (net of the $0.2 million discount) is included as Other long-term liability on the statement of financial position (a total of $1.9 million of fees, net of discounts, are deferred as at March 31, 2022). Subsequent to March 31, 2022, Resverlogix and EVERSANA expanded their partnership to include not only COVID-19 but also cardiovascular and pulmonary arterial hypertension indications (the “Amendment”). In connection with the Amendment, if Resverlogix and EVERSANA have not launched a product by July 1, 2022, Resverlogix will make monthly payments to EVERSANA, commencing in July 2022, equal to 50% of the deferred fees for the corresponding month twelve months prior.
and now we've GIVEN AWAY Cario and PAH to eversana?
This story just keeps getting better and better. i am amazed to the extent with how this has been run into the ground. actually, it seems like we've been run under the ground, we're now 6 feet under and retail seems to be the last ones to know!
AGM cant come fast enuf for me....